SCHEMBL4476170

SCHEMBL4476170

NC(=O)C(Br)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.38
TPMT P51580 1/20 0.38
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
EPHX1 P07099 1/20 0.35
TSHR P16473 1/20 0.35
CYP3A4 P08684 2/20 0.33
MCL1 Q07820 1/20 0.33
TP53 P04637 1/20 0.33
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32
PARP1 P09874 1/20 0.32
GRM4 Q14833 1/20 0.32
RAB9A P51151 1/20 0.32
RXRA P19793 1/20 0.31
RXRB P28702 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29633174 0.84 CES2 (0.37) EPHX1
SCHEMBL7471497 0.80 PARP1 (0.48) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL28388631 0.80 TPMT (0.44) APPTPMTTSHRIDO1TDO2
SCHEMBL28510114 0.79 TPMT (0.42) APPTPMTHTR3EHTR3BHTR3A
SCHEMBL7473524 0.78 CYP2C9 (0.44) TSHRCYP3A4RAB9A
SCHEMBL10754738 0.78 KDM4E (0.37) TPMTEPHX1TSHRCYP3A4MCL1
SCHEMBL22445731 0.78 BRD4 (0.39) APPTPMTTSHRRXRARXRB
SCHEMBL5385340 0.74 APP (0.57) APPTPMTHTR3EHTR3BHTR3A
SCHEMBL7680152 0.74 CES2 (0.44) EPHX1IDO1TDO2PARP1
SCHEMBL27175927 0.74 CES2 (0.48) EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498441-B2 Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders SCHERING CORPORATION (US) 2009-03-03 US disclosed
EP-1601664-B1 BIARYLTETRAHYDROISOQUINOLINE PIPERIDINES AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS SCHERING CORP (US) 2008-04-30 EP disclosed
CN-1777596-A Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders SCHERING CORP (US) 2006-05-24 CN disclosed
EP-1601664-A1 BIARYLTETRAHYDROISOQUINOLINE PIPERIDINES AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS SCHERING CORPORATION (US) 2005-12-07 EP disclosed
WO-2004078745-A1 BIARYLTETRAHYDROISOQUINOLINE PIPERIDINES AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS SCHERING CORPORATION (US) 2004-09-16 WO disclosed
US-20040176355-A1 Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders SCHERING CORPORATION 2004-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176355-A1 Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders MCHR1, MCHR2, MC4R APP 4393/4885TPMT 3749/4885HTR3E 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.